神州细胞：2025年预亏5.2亿元~5.8亿元 同比由盈转亏

Core Viewpoint - Shenzhou Cell (688520) is expected to report a net loss attributable to shareholders of the parent company between -580 million yuan and -520 million yuan for 2025, a significant decline from a net profit of 112 million yuan in the same period last year, indicating a shift from profit to loss due to industry healthcare cost control policies and price reductions of its core product Anjiah [2] Group 1 - The company's core product sales revenue has significantly decreased, leading to an overall decline in operating income compared to the same period last year [2] - The ongoing deepening of healthcare cost control policies in the industry has adversely affected the company's financial performance [2] - The price reductions of the core product Anjiah have contributed to the decline in sales revenue [2]